Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

380
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

457
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

MYCOPHENOLATE MOFETIL IN COMBINATION WITH INTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PRELIMINARY STUDY

Pages

  1-5

Abstract

 BACKGROUND: The efficacy of MYCOPHENOLATE MOFETIL (MMF) plus INTERFERON BETA-1A (IFNB-1a) in treatment of relapsing- remitting multiple sclerosis (RRMS) was evaluated.METHODS: This was a pilot study with randomized, double-blinded, placebo-controlled design. Patients with RRMS and Expanded Disability Status Scale score (EDSS) of < 6.0 were included. Those with relapse within the previous two months and prior use of immunomodulatory/immunosuppressive drugs were excluded. Patients were randomized into MMF (n=13) and placebo (n=13) groups and received weekly intramuscular IFNB-1a plus either MMF or placebo.MMF started by 500 mg/d for one week and weekly escalated by 500 mg/d, until target divided dose of 2000 mg/d and continued for 12 months. Radiologic and clinical assessments were performed at baseline and then at month 12.RESULTS: After one year of therapy, difference between the two groups in number of new T2 lesions was not statistically significant (0.54 ± 0.77 in MMF vs.1.85 ± 3.2 in placebo group, p=0.169) . Two patients in the placebo group had gadolinium-enhanced lesions and one patient had relapse. There were 3 patients in each group with more than one point progression in EDSS. Common side effect in the MMF group included gastrointestinal upset, but no patient discontinued the treatment.CONCLUSIONS: Combination of MMF with IFNB-1a in patients with RRMS is well tolerated, but the efficacy of such combination was not statistically significant in this pilot study and deserves further investigation with a larger sample size and a longer follow-up.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    ETEMADIFAR, MASOUD, KAZEMI, MOJTABA, CHITSAZ, AHMAD, HEKMATNIA, ALI, TAYARI, NAZILA, GHAZAVI, AMIRHOSSEIN, & MAGHZI, AMIR HADI. (2011). MYCOPHENOLATE MOFETIL IN COMBINATION WITH INTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PRELIMINARY STUDY. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), 16(1), 1-5. SID. https://sid.ir/paper/577556/en

    Vancouver: Copy

    ETEMADIFAR MASOUD, KAZEMI MOJTABA, CHITSAZ AHMAD, HEKMATNIA ALI, TAYARI NAZILA, GHAZAVI AMIRHOSSEIN, MAGHZI AMIR HADI. MYCOPHENOLATE MOFETIL IN COMBINATION WITH INTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PRELIMINARY STUDY. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS)[Internet]. 2011;16(1):1-5. Available from: https://sid.ir/paper/577556/en

    IEEE: Copy

    MASOUD ETEMADIFAR, MOJTABA KAZEMI, AHMAD CHITSAZ, ALI HEKMATNIA, NAZILA TAYARI, AMIRHOSSEIN GHAZAVI, and AMIR HADI MAGHZI, “MYCOPHENOLATE MOFETIL IN COMBINATION WITH INTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PRELIMINARY STUDY,” JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), vol. 16, no. 1, pp. 1–5, 2011, [Online]. Available: https://sid.ir/paper/577556/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top